Antibiotics and Antimicrobial Resistance (AMR) in Chronic Lung Disease: Patient Perspectives |
Introduction
Antibiotics are a crucial treatment for many people living with chronic lung conditions where lung infection is one of the most common causes of illness. Chronic infection and flare-ups in conditions such as bronchiectasis, COPD and cystic fibrosis are often effectively treated by antibiotics.
Antimicrobial Resistance (AMR) is when the germs that cause infections no longer respond to the antibiotic medicines that treat them. These resistant germs can then spread and pose a greater threat to our health.
In this survey, we ask you to tell us about your experience and understanding of antibiotics and Antimicrobial Resistance (AMR). Your perspectives are very important to help us understand how to tackle AMR in the future. We will use the survey data to inform the respiratory community and identify priorities for education and research.
The survey will take about 15 minutes to complete and is anonymous.
If answering any of these questions causes you any concern about your health, we encourage you to talk to your healthcare professional. You can also read more about AMR at https://europeanlung.org/en/information-hub/living-with-a-lung-condition/antimicrobial-resistance-amr/ (you can use your browser options to translate this page)
The survey has been developed by members of the AMR-Lung (Antimicrobial Resistance in Lung Infections) Clinical Research Collaboration and patient representatives from the European Lung Foundation. If you have any questions about this survey or the AMR-Lung Clinical Research Collaboration please contact jeanette.boyd@europeanlung.org
Thank you for your help.
